| Ticker: CPWY | 995 Benecia Avenue | |
| Exchange: NASDAQ-National Market | Sunnyvale, California 94086 | |
| Industry: Manufacturing | (408) 737-0505 |
| Type of Shares: | Common Shares | Filing Date: | 4/17/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 6/12/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $15.00 - $17.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $19.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.33 | |
| Offering Amount: | $40,000,000 | Selling: | $0.80 | |
| Expenses: | $1,100,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,086,909 |
| Manager | Tier | Phone |
| Morgan Stanley & Co. Incorporated | Lead Manager | (212) 703-4797 |
| Cowen & Company | Co-manager | (212) 495-6000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.12 | $1.08 | $0.09 | Assets: | $15.82 |
| Net Income: | -$9.66 | -$6.73 | -$7.34 | Liabilities: | $10.44 |
| EPS: | -$1.39 | -$0.97 | Equity: | $5.38 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops and manufactures minimally invasive systems to diagnose and treat cardiac tachyarrhythmias which, if untreated, can cause palpitations, fainting and sudden cardiac arrest. The company is developing products designed to provide integrated system solutions for the successful diagnosis and treatment of ventricular tachycardia and atrial fibrillation, two of the most serious and prevalent types of abnormally rapid heart rhythms. The company's products consist of systems for diagnostic mapping, or locating the source of the tachyarrythmia within the heart, and for performing ablation treatment, a nonsurgical, minimally invasive technique for neutralizing heart tissue responsible for starting or maintaining a dangerous heart rhythm. Current mapping will substantially shorten mapping and ablation procedure time and provide safe and more effective treatments of ventricular tachycardia and atrial fibrillation than other current forms of therapy. |
| Use of Proceeds |
| Proceeds from the offering will be used for funding research and development, including clinical trials, marketing and sales, general and administrative support, capital expenditures and working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.